 All patients will be identified and recruited from any of the Liver or GI clinics in the Outpatient Center, UAMS. For the second aim Group B - the longitudinal part of the study - patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor Dexcom, San Diego, CA for 3 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks, according to the manufacturers recommendations. The continuous glucose monitor will record patients glucose from the odd to the even research visit i.e. from 1 to 2, 3 to 4, 5 to 6, and 7 to 8. On the last day the continuous glucose monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting 8-12 hours: HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin. Anthropometrics height, weight, and waist circumference will be obtained as well Research Visit 8, see calendar. In order not to affect glucose control during the study period glucose reads from the continuous glucose monitor will not be disclosed to the patient until the end of the study. 